Literature DB >> 25934114

Lowering the dietary omega-6: omega-3 does not hinder nonalcoholic fatty-liver disease development in a murine model.

Reilly T Enos1, Kandy T Velázquez1, Jamie L McClellan1, Taryn L Cranford1, Michael D Walla2, E Angela Murphy3.   

Abstract

It is hypothesized that a high dietary n-6:n-3 (eg, 10-20:1) is partly responsible for the rise in obesity and related health ailments. However, no tightly controlled studies using high-fat diets differing in the n-6:n-3 have tested this hypothesis. The aim of the study was to determine the role that the dietary n-6:n-3 plays in non-alcoholic fatty-liver disease (NAFLD) and colitis development. We hypothesized that reducing the dietary n-6:n-3 would hinder the development of NAFLD and colitis. Male C57BL/6 J mice were fed high-fat diets, differing in the n-6:n-3 (1:1, 5:1, 10:1, 20:1), for 20 weeks. Gas chromatography-mass spectrometry was used to analyze the hepatic phospholipid arachidonic acid (AA):eicosapentaenoic acid and AA:docosahexaenoic acid. Hepatic metabolism, inflammatory signaling, macrophage polarization, gene expression of inflammatory mediators, oxidative and endoplasmic reticulum stress, and oxidative capacity were assessed as well as colonic inflammatory signaling, and gene expression of inflammatory mediators and tight-junction proteins. Although reducing the dietary n-6:n-3 lowered the hepatic phospholipid AA:eicosapentaenoic acid and AA:docosahexaenoic acid in a dose-dependent manner and mildly influenced inflammatory signaling, it did not significantly attenuate NAFLD development. Furthermore, the onset of NAFLD was not paired to colitis development or changes in tight-junction protein gene expression. In conclusion, reducing the dietary n-6:n-3 did not attenuate NAFLD progression; nor is it likely that colitis, or gut permeability, plays a role in NAFLD initiation in this model.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Colitis; High-fat diet; Murine model; Nonalcoholic fatty-liver disease; Omega-6:omega-3; α-Linolenic acid

Mesh:

Substances:

Year:  2015        PMID: 25934114      PMCID: PMC4451001          DOI: 10.1016/j.nutres.2015.04.003

Source DB:  PubMed          Journal:  Nutr Res        ISSN: 0271-5317            Impact factor:   3.315


  45 in total

1.  Polyunsaturated fatty acid pattern in liver and erythrocyte phospholipids from obese patients.

Authors:  Alejandra Elizondo; Julia Araya; Ramón Rodrigo; Jaime Poniachik; Attila Csendes; Fernando Maluenda; Juan C Díaz; Cinzia Signorini; Cristiana Sgherri; Mario Comporti; Luis A Videla
Journal:  Obesity (Silver Spring)       Date:  2007-01       Impact factor: 5.002

2.  Importance of the omega-6/omega-3 balance in health and disease: evolutionary aspects of diet.

Authors:  Artemis P Simopoulos
Journal:  World Rev Nutr Diet       Date:  2011-08-05       Impact factor: 0.575

Review 3.  Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis.

Authors:  Helen M Parker; Nathan A Johnson; Catriona A Burdon; Jeffrey S Cohn; Helen T O'Connor; Jacob George
Journal:  J Hepatol       Date:  2011-10-21       Impact factor: 25.083

4.  Insight into the impact of dietary saturated fat on tissue-specific cellular processes underlying obesity-related diseases.

Authors:  Reilly T Enos; Kandy T Velázquez; E Angela Murphy
Journal:  J Nutr Biochem       Date:  2014-03-12       Impact factor: 6.048

5.  IL-6 strikes a balance in metabolic inflammation.

Authors:  Anthony J Covarrubias; Tiffany Horng
Journal:  Cell Metab       Date:  2014-06-03       Impact factor: 27.287

Review 6.  Diets and nonalcoholic fatty liver disease: the good and the bad.

Authors:  Mohamed Asrih; François R Jornayvaz
Journal:  Clin Nutr       Date:  2013-11-08       Impact factor: 7.324

7.  Hepatic n-3 polyunsaturated fatty acid depletion promotes steatosis and insulin resistance in mice: genomic analysis of cellular targets.

Authors:  Barbara D Pachikian; Ahmed Essaghir; Jean-Baptiste Demoulin; Audrey M Neyrinck; Emilie Catry; Fabienne C De Backer; Nicolas Dejeans; Evelyne M Dewulf; Florence M Sohet; Laurence Portois; Louise Deldicque; Olivier Molendi-Coste; Isabelle A Leclercq; Marc Francaux; Yvon A Carpentier; Fabienne Foufelle; Giulio G Muccioli; Patrice D Cani; Nathalie M Delzenne
Journal:  PLoS One       Date:  2011-08-10       Impact factor: 3.240

8.  Peroxisome proliferator-activated receptor α activation induces hepatic steatosis, suggesting an adverse effect.

Authors:  Fang Yan; Qi Wang; Chao Xu; Mingfeng Cao; Xiaoming Zhou; Tingting Wang; Chunxiao Yu; Fei Jing; Wenbin Chen; Ling Gao; Jiajun Zhao
Journal:  PLoS One       Date:  2014-06-13       Impact factor: 3.240

9.  High fat diet-induced gut microbiota exacerbates inflammation and obesity in mice via the TLR4 signaling pathway.

Authors:  Kyung-Ah Kim; Wan Gu; In-Ah Lee; Eun-Ha Joh; Dong-Hyun Kim
Journal:  PLoS One       Date:  2012-10-16       Impact factor: 3.240

Review 10.  Multiple hits, including oxidative stress, as pathogenesis and treatment target in non-alcoholic steatohepatitis (NASH).

Authors:  Akinobu Takaki; Daisuke Kawai; Kazuhide Yamamoto
Journal:  Int J Mol Sci       Date:  2013-10-15       Impact factor: 5.923

View more
  11 in total

1.  Loss of monocyte chemoattractant protein-1 expression delays mammary tumorigenesis and reduces localized inflammation in the C3(1)/SV40Tag triple negative breast cancer model.

Authors:  Taryn L Cranford; Kandy T Velázquez; Reilly T Enos; Jackie E Bader; Meredith S Carson; Ioulia Chatzistamou; Mitzi Nagarkatti; E Angela Murphy
Journal:  Cancer Biol Ther       Date:  2017-01-11       Impact factor: 4.742

2.  High-fat diets rich in saturated fat protect against azoxymethane/dextran sulfate sodium-induced colon cancer.

Authors:  Reilly T Enos; Kandy T Velázquez; Jamie L McClellan; Taryn L Cranford; Mitzi Nagarkatti; Prakash S Nagarkatti; J Mark Davis; E Angela Murphy
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2016-03-31       Impact factor: 4.052

3.  Repeated clodronate-liposome treatment results in neutrophilia and is not effective in limiting obesity-linked metabolic impairments.

Authors:  Jackie E Bader; Reilly T Enos; Kandy T Velázquez; Meredith S Carson; Alex T Sougiannis; Owen P McGuinness; Cory M Robinson; E Angela Murphy
Journal:  Am J Physiol Endocrinol Metab       Date:  2018-12-21       Impact factor: 5.900

4.  Role of MCP-1 on inflammatory processes and metabolic dysfunction following high-fat feedings in the FVB/N strain.

Authors:  T L Cranford; R T Enos; K T Velázquez; J L McClellan; J M Davis; U P Singh; M Nagarkatti; P S Nagarkatti; C M Robinson; E A Murphy
Journal:  Int J Obes (Lond)       Date:  2015-12-01       Impact factor: 5.095

5.  High-fat diet-fed ovariectomized mice are susceptible to accelerated subcutaneous tumor growth potentially through adipose tissue inflammation, local insulin-like growth factor release, and tumor associated macrophages.

Authors:  Jackie Bader; Meredith Carson; Reilly Enos; Kandy Velazquez; Alexander Sougiannis; Udai Singh; William Becker; Mitzi Nagarkatti; Daping Fan; Angela Murphy
Journal:  Oncotarget       Date:  2020-12-08

6.  Effects of high fat diet-induced obesity on mammary tumorigenesis in the PyMT/MMTV murine model.

Authors:  Taryn L Cranford; Kandy T Velázquez; Reilly T Enos; Alexander T Sougiannis; Jackie E Bader; Meredith S Carson; Rebecca R Bellone; Ioulia Chatzistamou; Mitzi Nagarkatti; E Angela Murphy
Journal:  Cancer Biol Ther       Date:  2018-11-02       Impact factor: 4.875

7.  A Low Dose of Dietary Quercetin Fails to Protect against the Development of an Obese Phenotype in Mice.

Authors:  Reilly T Enos; Kandy T Velázquez; Meredith S Carson; Jamie L McClellan; Prakash Nagarkatti; Mitzi Nagarkatti; J Mark Davis; E Angela Murphy
Journal:  PLoS One       Date:  2016-12-13       Impact factor: 3.240

8.  Short-term pyrrolidine dithiocarbamate administration attenuates cachexia-induced alterations to muscle and liver in ApcMin/+ mice.

Authors:  Aditi A Narsale; Melissa J Puppa; Justin P Hardee; Brandon N VanderVeen; Reilly T Enos; E Angela Murphy; James A Carson
Journal:  Oncotarget       Date:  2016-09-13

9.  n-3 PUFAs reduce tumor load and improve survival in a NASH-tumor mouse model.

Authors:  Marie Liebig; Dirk Dannenberger; Brigitte Vollmar; Kerstin Abshagen
Journal:  Ther Adv Chronic Dis       Date:  2019-09-05       Impact factor: 5.091

10.  Macrophage tumor necrosis factor-alpha deletion does not protect against obesity-associated metabolic dysfunction.

Authors:  Ahmed K Aladhami; Christian A Unger; Shannon L Ennis; Diego Altomare; Hao Ji; Marion C Hope; Kandy T Velázquez; Reilly T Enos
Journal:  FASEB J       Date:  2021-07       Impact factor: 5.834

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.